Head of Pediatric Follow-up Group at University of Bergen and the Pediatric Clinical Trials Unit at Haukeland University Hospital.

Her research is especially focused on nephrology, immunology and clinical trials. As part of the board in NorCRIN (since 2012) and NorPedMed (since 2014) she works for more clinical trials in Norway. She is ECRINs Norwegian scientific representative, leader of the Norwegian Pediatric Nephrology Group, national ESPN-representative and part of the CKJ editorial board.

Head of Teaching, Department of Clinical Science, University of Bergen  

MED9: Pediatric nephrology and rheumatology. General Pediatrics. Acute Heart Lung Resuscitation. Paediatric Pharmacology. Intoxications. Paediatric Fluid Therapy. Social Pediatrics.

MED5: Communication with children and adolescents

GCP901: Course leader. Course in clinical studies including ICH-GCP

MEDMET1: ICH-Good Clinical Practice

NUCLI352: Pediatric Nephrology

Interview

• Tøndel, Camilla (2024). Evolving screening and diagnosis strategies in Fabry disease. (external link)
• Tøndel, Camilla; Berg, Are Stuwitz (2024). Vaksine mot vannkopper. (external link)
• Tøndel, Camilla (2024). Foreslår at alle barn skal få vaksine mot vannkopper fra neste år. (external link)
• Cox, Rebecca Jane; Tøndel, Camilla; Spurkland, Anne et al. (2023). Bør alle norske barn vaksineres mot vannkopper?. (external link)
• Tøndel, Camilla (2022). Katrine (47) har meldt seg frivillig til å teste en ny, norsk vaksine. Håpet er at den skal beskytte lenger enn de man har hatt til nå . (external link)
• Tøndel, Camilla (2022). Lovende resultater av mulig ny behandling av Fabry sykdom: – Stor praktisk betydning. (external link)
• Tøndel, Camilla (2022). Nye behandlingsformer for Fabrys sykdom under utprøving. (external link)
• Tøndel, Camilla (2021). Her settes første dose av norskutviklet koronavaksine. (external link)
• Tøndel, Camilla (2015). Kreft hos barn og betydning av klinisk utprøving hos barn. (external link)
• Tøndel, Camilla (2015). Har testet medisiner på 400 barn. (external link)
• Gunnes, Maria Winther; Tøndel, Camilla (2014). Kampen mot kreft. (external link)
• Halvorsen, Thomas; Tøndel, Camilla (2014). Forskning på legemidler til barn må gjøres i Norge. (external link)
• Tøndel, Camilla (2013). Forskning på medisiner til barn, Ekko . (external link)
• Tøndel, Camilla; Svarstad, Einar (2013). Enzyme replacement in Fabry disease. (external link)

Poster

• Bernat, John; Hughes, Derralynn A.; Linhart, Aleš et al. (2024). Assessment of immunogenicity from the pegunigalsidase alfa clinical trial program: Integrated analysis of de novo and treatment-boosted anti-drug antibodies. (external link)
• Hughes, Derralynn A.; Bernat, John; Linhart, Aleš et al. (2024). Tolerability of pegunigalsidase alfa across the clinical program: Integrated analysis of infusion-related reactions by dosing regimens. (external link)
• Mehta, Ankit; Wallace, Eric; Linhart, Aleš et al. (2024). Tolerability of pegunigalsidase alfa across the clinical program: Integrated analysis of infusion-related reactions by prior enzyme replacement therapy. (external link)
• Tøndel, Camilla; Pisani, Antonio; Bernat, John A. et al. (2024). Cross-Sectional Analysis of Organ Involvement and Biomarker Levels in Patients With and Without Antidrug Antibodies to Enzyme Replacement Therapies for Fabry Disease. (external link)
• Warnock, David G; Goker-Alpan, Ozlem; Bernat, John et al. (2023). Pooled analysis of the effect of pegunigalsidase alfa on renal function: Data from 113 patients in the pegunigalsidase alfa clinical trial program. (external link)
• Wallace, Eric; Goker-Alpan, Ozlem; Holida, Myrl et al. (2023). First results of a head-to-head trial of pegunigalsidase alfa vs. agalsidase beta in Fabry disease: 2 year results of the phase 3 randomized, double-blind, BALANCE study. (external link)
• Najafian, Behzad; Nicholls, Kathleen; West, Michael L et al. (2023). The spectrum of podocyte injury in later onset (LO) variants of Fabry disease (FD). (external link)
• Smerkous, David; Mauer, Michael; Tøndel, Camilla et al. (2023). Development of an online cloud-based tool for automatic measurement of foot process width (FPW) using deep learning (DL): Applications in assessment of podocyte injury in Fabry disease (FD). (external link)
• Bernat, John; Holida, Myrl; Longo, Nicola et al. (2023). Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with Fabry disease: Two-year interim results from the ongoing phase 3 BRIGHT51 open-label extension study. (external link)
• Salvador, Cathrin Lytomt; Flemmen, Per Tryggve Kjelland; Woldseth, Berit et al. (2023). Reduced renal function and other factors influence the measured level of glycosaminoglycans (GAGs) and could lead to diagnostic misinterpretation. (external link)
• Tøndel, Camilla; Warnock, David G; Goker-Alpan, Ozlem et al. (2023). Pooled analysis of the effect of pegunigalsidase alfa on renal function: Data from 113 patients in the pegunigalsidase alfa clinical trial program. (external link)
• Kopsidas, John; Hofstraat, Sanne; Salmanton-García, Jon et al. (2022). Capacity mapping and building for pediatric vaccine trials across Europe with VACCELERATE’s harmonized assessment tool. (external link)
• Tøndel, Camilla; Wallace, Eric; Rocco, Rossana et al. (2022). Pharmacokinetic (PK) Results From a Phase 3 Trial to Evaluate Pegunigalsidase Alfa Every 4 Weeks (Q4W) in Patients (Pts) With Fabry Disease Previously Treated With Agalsidase Beta or Agalsidase Alfa. (external link)
• Najafian, Behzad; Silvestroni, Aurelio; Sokolovskiy, Alexey et al. (2022). Globotriaosylceramide (GL3) accumulation in Fabry podocytes in female patients is progressive with age and associated with podocyte loss and proteinuria. (external link)
• Holida, Myrl; Bernat, John; Longo, Nicola et al. (2022). Safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with Fabry disease: Results from the phase 3, open-label, BRIGHT study. (external link)
• Braun, Fabian; Abed, Ahmed; Woidy, Mathias et al. (2021). Synuclein Alpha Accumulation Drives Lysosomal Dysfunction in Fabry Podocytopathy. (external link)
• Bradley, John S; Makieieva, Natalia; Tøndel, Camilla et al. (2021). Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Pediatric Participants With Confirmed or Suspected Gram-negative Bacterial Infections: A Phase 1b, Open-label, Single-dose Clinical Trial. (external link)
• Lillås, Bjørn Steinar; Tøndel, Camilla; Vikse, Bjørn Egil (2020). Low Birth Weigth Is Associated With Lower Measured Glomerular Filtration Rate In Adult Age. (external link)
• Linhart, Aleš; Dostalova, Gabriela; Nicholls, Kathleen et al. (2020). Switching from agalsidase alfa to pegunigalsidase alfa for treating Fabry disease: One year of treatment data from BRIDGE, a phase III open label study . (external link)
• Tøndel, Camilla; Linhart, Aleš; Dostalova, Gabriela et al. (2020). Switching from Agalsidase Alfa to Pegunigalsidase Alfa for Treating Fabry Disease: One Year of Treatment Data from Bridge, a Phase 3 Open-Label Study. (external link)
• Eikrem, Øystein Solberg; Delaleu, Nicolas; Strauss, Philipp et al. (2020). Systems Analyses of Renal Fabry Transcriptome and Response to Enzyme Replacement Therapy (ERT) Identifies a Cross-Validated and Druggable ERT-Resistant Module. (external link)
• Smeets, Nori JL; Teunissen, E; Teesselink, E et al. (2020). Diagnosis of AKI using Iohexol in critically ill children and neonates: preliminary results of the HERO study. (external link)
• Holida, Myrl; Bernat, John; Longo, Nicola et al. (2019). New Regimen of Once Every 4 Weeks 2 mg/kg of Pedunigalsidase Alfa for Treating Fabry Disease - Prelimenary Results of a Phase 3 Study. (external link)
• Svarstad, Einar; Skrunes, Rannveig; Davidsen, Einar Skulstad et al. (2019). Clinical Consequences of Paired Cardiac and Kidney Biopsies in a Treatment Naive Female Fabry Patient with a Classical Mutation and Minor Clnical Symptoms. (external link)
• Linhart, Aleš; Nicholls, Kathy; West, Michael et al. (2019). Prelimenary Results of the Fabry Disease Phase III Open Label Study of Switching from Agalsidase Alfa to Pegunigalsidase Alfa. (external link)
• Lillås, Bjørn Steinar; Tøndel, Camilla; Gjerde, Anna et al. (2019). Measurement of renal functional response using iohexol clearance. (external link)
• Najafian, Behzad; Tøndel, Camilla; Svarstad, Einar et al. (2019). Accumulation of Globotriaosylceramide in Podocytes (PC) in Fabry Nephropathy Is Associated with Progressive PC Loss. (external link)
• Warnock, David G; Wallace, Eric; Schiffman, Raphael et al. (2019). Analysis of the baseline characteristics of Fabry disease patients screened for the pegunigalsidase alfa Phase III BALANCE study . (external link)
• Holida, Myrl; Bernat, John; Longo, Nicola et al. (2019). Once every 4 weeks 2 mg/kg of pegunigalsidase alfa for treating Fabry disease- preliminary result of a phase 3 study. (external link)
• Linhart, Aleš; Nicholls, Kathy; West, Michael et al. (2019). Pegunigalsidase alfa for the treatment of Fabry disease - Phase III open label, switch over study from agalsidase alfa - Preliminary results. (external link)
• Najafian, Behzad; Tøndel, Camilla; Svarstad, Einar et al. (2018). Podocyte structural parameters predict glomerular filtration rate (GFR) loss in male patients with classic Fabry disease. (external link)
• Tøndel, Camilla; Salvador, Cathrin Lytomt; Hufthammer, Karl Ove et al. (2018). IOHEXOL CLEARANCE IN CHILDREN WITH LOW GFR: COMPARISON OF 24 HOURS SINGLE-POINT GFR AND MULTIPLE-POINT GFR. (external link)
• Wanner, Christoph; Elliot, PM; Formin, V et al. (2018). KIDNEY-SPECIFIC THERAPEUTIC GOALS FOR FABRY DISEASE BASED ON EUROPEAN EXPERT CONSENSUS RECOMMENDATIONS AND SYSTEMATIC REVIEW OF PUBLISHED EVIDENCE. (external link)
• Eide, Thea Tislevoll; Brun, Atle; Brackman, Damien et al. (2018). SINGLE INTRAVENOUS ACCESS FOR MEASUREMENT OF GLOMERULAR FILTRATION RATE IN CHILDREN AFTER MARKER INJECTION. (external link)
• Eikrem, Øystein Solberg; Strauss, Philipp; Sekulic, Miroslav et al. (2018). Fabry nephropathy: Transcriptome sequencing of microdissected renal compartments from archival kidney biopsies at baseline, and after 5 & 10 years of enzyme replacement therapy. (external link)
• Najafian, Behzad; Tøndel, Camilla; Svarstad, Einar et al. (2017). Podocyte globotriaosylceramide (GL-3) content strongly impacts age-dependent podocyte loss in ERT-naïve male Fabry patients. (external link)
• Ramaswami, Uma; Wijburg, Frits; Bichet, Daniel G et al. (2017). A randomized, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms (FIELD study): GL-3 clearance from kidney cells. (external link)
• Ramaswami, Uma; Wijburg, Frits; Bichet, Daniel G et al. (2017). A randomized, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms (FIELD study): GL-3 clearance from superficial skin capillary endothelium. (external link)
• Svarstad, Einar; Skrunes, Rannveig; Leh, Sabine Maria et al. (2017). Simplified Clinical Pre-histologic Scoring Method of Kidney Biopsies in Fabry Disease. (external link)
• Tøndel, Camilla; Salvador, Cathrin Lytomt; Hufthammer, Karl Ove et al. (2017). Single-point iohexol plasma clearance in children: validation of multiple formulas and sampling times. (external link)
• Chang, Fu-Pang; Mauer, Michael; Sokolovskiy, Alexey et al. (2016). Differential response of glomerular parietal epithelial cells and podocytes to enzyme replacement therapy in Fabry nephropathy. (external link)
• Najafian, Behzad; Tøndel, Camilla; Svarstad, Einar et al. (2016). Podocyte Hypertrophy and Globotriaosylceramide (GL-3) Accumulation Are Strong Predictors of Podocyte Loss in Enzyme Replacement Therapy Naïve Male Patients with Fabry Disease. (external link)
• Thorsteinsdottir, Hjørdis; Salvador, Cathrin Lytomt; Tøndel, Camilla et al. (2016). GDF-15 in plasma and urine as a marker of kidney function in children . (external link)
• Salvador, Cathrin Lytomt; Rowe, Alexander D.; Bjerre, Anna Kristina et al. (2016). Glomerular filtration rate (GFR) strongly influences guanidinoacetic acid (GAA) in plasma and urine. (external link)
• Skrunes, Rannveig; Larsen, Kristin Kampevold; Leh, Sabine Maria et al. (2015). FABRY DISEASE DIAGNOSED IN LIVING DONOR KIDNEY TRANSPLANT BIOPSY. (external link)
• Skrunes, Rannveig; Svarstad, Einar; Larsen, Kristin Kampevold et al. (2015). DIFFERENTIAL KIDNEY EFFECTS OF HIGH AND LOW ENZYME DOSE IN MALE SIBLINGS TREATED FOR 13 YEARS . (external link)
• Skrunes, Rannveig; Tøndel, Camilla; Larsen, Kristin Kampevold et al. (2015). LONG-TERM ENZYME REPLACEMENT THERAPY (ERT) BENEFITS THE GLOMERULI MORE THAN THE VASCULATURE IN YOUNGER FABRY NEPHROPATHY . (external link)
• Najafian, Behzad; Tøndel, Camilla; Svarstad, Einar et al. (2015). Podocyte Globotriaosylceramide (GL3) Accumulation in Fabry Disease Is Influenced by Age and Genotype . (external link)
• Skrunes, Rannveig; Larsen, Kristin Kampevold; Svarstad, Einar et al. (2014). Fabry nephropathy (FN) outcome and the impact of diagnostic kidney biopsies after 10 years enzyme replacement therapy (ERT). (external link)
• Tøndel, Camilla; Larsen, Kristin Kampevold; Skrunes, Rannveig et al. (2014). Renal Biopsies after 6-11 Years of Enzyme Replacement Therapy in 9 Young Classic Fabry Disease Patients. (external link)
• Najafian, Behzad; Mauer, Michael; Svarstad, Einar et al. (2014). Enzyme Replacement Therapy (ERT) in Fabry Disease (FD) Reduces Podocyte (PC) Globotriaosylceramide (GL3) Content within a Year (yr). (external link)
• Tøndel, Camilla; Kanai, Takahiro; Larsen, Kristin Kampevold et al. (2014). Five Children with Fabry Disease and Significant Tissue Damage in Renal Biopsies Despite Normal Clinical Renal Parameters. (external link)
• Tol, Linda van der; Vogt, L; Florquin, S et al. (2014). Consensus recommendation on Fabry disease diagnosis in adult patients with kidney disease. (external link)
• Salvador, Cathrin Lytomt; Tøndel, Camilla; Mørkrid, Lars et al. (2013). Glomerular Filtration Rate (GFR) measured by Iohexol Clearance in Children; a comparison between venous samples and dried spots. (external link)
• Tøndel, Camilla; Bolann, Bjørn Johan; Salvador, Cathrin Lytomt et al. (2013). Glomerular filtration rate (GFR) measured by iohexolclearance in children; how many sample points are necessary?. (external link)
• Tøndel, Camilla; Svarstad, Einar; Bostad, Leif (2009). Renal follow-up biopsies in young male Fabry patients on enzyme replacement therapy. (external link)
• Tøndel, Camilla; Bertelsen, AK; Bostad, Leif et al. (2008). Fabry disease: Unusual symptoms in two male children treated with lamotrigine and fabrazyme, respectively. (external link)
• Tøndel, Camilla; Vikse, Bjørn Egil; Iversen, Bjarne Magnus et al. (2008). Renal biopsies in children in Norway 1988-2005: clinical variables, complications and prognosis. (external link)
• Tøndel, Camilla; Aakre, Kristin M.; Brun, Atle et al. (2008). Formula GFR overestimates Renal Function in Children and Adult Males with Fabry Disease and Stage 1-2 CKD. (external link)

Doctoral dissertation

• Lillås, Bjørn Steinar Demma; Tøndel, Camilla; Vikse, Bjørn Egil et al. (2024). Impact of birth weight on kidney health in middle-aged adults : Results from the Haugesund Low Birth Weight Study. (external link)
• Strauss, Philipp; Eikrem, Øystein Solberg; Marti, Hans Peter et al. (2023). From archival tissues to systems biology: Using transcriptomics to investigate the progression of kidney disease. (external link)
• Salvador, Cathrin Lytomt; Mørkrid, Lars; Bergan, Stein et al. (2020). Estimation and measurement of glomerular filtration rate in children. (external link)
• Skrunes, Rannveig; Tøndel, Camilla (2017). Hereditary renal disease in the Norwegian population, with a focus on Fabry disease. (external link)
• Tøndel, Camilla (2013). Markers of nephropathy in young Fabry disease patients; role of kidney biopsies and functional measurement. (external link)

Academic article

• Hopkin, Robert J.; Martins, Ana; Alton, Julia et al. (2024). Plain Language Summary: Looking at treatment outcomes in people with Fabry disease who started agalsidase beta before the age of 30 years. (external link)
• Burlina, Alessandro; Duning, Thomas; Fernandez-Martin, Julian et al. (2024). Fabry disease: current gaps and actionable solutions to improve Fabry patients’ clinical journey. (external link)
• Bredholt, Geir; Sævik, Marianne; Søyland, Hanne et al. (2024). Three doses of Sars-CoV-2 mRNA vaccine in older adults result in similar antibody responses but reduced cellular cytokine responses relative to younger adults. (external link)
• Zhou, Fan; Vahokoski, Juha; Langeland, Nina et al. (2024). Impact of ageing on homologous and human-coronavirus-reactive antibodies after SARS-CoV-2 vaccination or infection. (external link)
• Holida, Myrl; Linhart, Aleš; Pisani, Antonio et al. (2024). A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies. (external link)
• Lillås, Bjørn Steinar Demma; Tøndel, Camilla; Melsom, Toralf et al. (2023). Renal Functional Response-Association With Birth Weight and Kidney Volume. (external link)
• Hansen, Lena; Brokstad, Karl Albert; Bansal, Amit et al. (2023). Durable immune responses after BNT162b2 vaccination in home-dwelling old adults. (external link)
• Braun, Fabian; Abed, Ahmed; Sellung, Dominik et al. (2023). Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy. (external link)
• Bichet, Daniel G; Hopkin, Robert J.; Aguiar, Patricio et al. (2023). Consensus recommendations for the treatment and management of patients with Fabry disease on migalastat: a modified Delphi study. (external link)
• Bradley, John S; Makieieva, Nataliia; Tøndel, Camilla et al. (2023). Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase 1b, Open-Label, Single-Dose Clinical Trial. (external link)
• Elsaid, Hassan Osman Alhassan; Rivedal, Mariell Lossius; Skandalou, Eleni et al. (2023). Proteomic analysis unveils Gb3-independent alterations and mitochondrial dysfunction in a gla ^−/− zebrafish model of Fabry disease. (external link)
• Wallace, Eric; Goker-Alpan, Ozlem; Wilcox, William R et al. (2023). Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: Results from the 2-year randomised phase III BALANCE study. (external link)
• Salvador, Cathrin Lytomt; Flemmen, Per Trygge Kjelland; Tøndel, Camilla et al. (2023). Renal function, sex and age influence purines and pyrimidines in urine and could lead to diagnostic misinterpretation. (external link)
• Linhart, Aleš; Dostalova, Gabriela; Nicholls, Kathy et al. (2023). Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study. (external link)
• Smerkous, David; Mauer, Michael; Tøndel, Camilla et al. (2023). Development of an automated estimation of foot process width using deep learning in kidney biopsies from patients with Fabry, minimal change, and diabetic kidney diseases.. (external link)
• Delaleu, Nicolas; Marti, Hans Peter; Strauss, Philipp et al. (2023). Systems analyses of the Fabry kidney transcriptome and its response to enzyme replacement therapy identified and cross-validated enzyme replacement therapy-resistant targets amenable to drug repurposing. (external link)
• Bansal, Amit; Trieu, Mai Chi; Mohn, Kristin Greve-Isdahl et al. (2023). Risk assessment and antibody responses to SARS-CoV-2 in healthcare workers. (external link)
• Elsaid, Hassan Osman Alhassan; Tjeldnes, Håkon; Rivedal, Mariell Lossius et al. (2022). Gene Expression Analysis in gla-Mutant Zebrafish Reveals Enhanced Ca²⁺ Signaling Similar to Fabry Disease. (external link)
• Gjerstad, Ann Christin; Skrunes, Rannveig; Tøndel, Camilla et al. (2022). Kidney biopsy diagnosis in childhood in the Norwegian Kidney Biopsy Registry and the long-term risk of kidney replacement therapy: a 25-year follow-up. (external link)
• Ertesvåg, Nina Urke; Xiao, Julie; Zhou, Fan et al. (2022). A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. (external link)
• Syre, Heidi; Obreque, Marius Eduardo Brå; Dalen, Ingvild et al. (2022). The performances of three commercially available assays for the detection of SARS‐CoV‐2 antibodies at different time points following SARS‐CoV‐2 infection. (external link)
• Hopkin, Robert J.; Cabrera, Gustavo; Jefferies, John et al. (2022). Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry registry. (external link)
• Elsaid, Hassan Osman Alhassan; Furriol, Jessica; Blomqvist, Maria et al. (2022). Reduced α-galactosidase A activity in zebrafish (Danio rerio) mirrors distinct features of Fabry nephropathy phenotype. (external link)
• Najafian, Behzad; Silvestroni, Aurelio; Sokolovskiy, Alexey et al. (2022). A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry disease. (external link)
• Fjelltveit, Elisabeth Berg; Blomberg, Bjørn; Kuwelker, Kanika et al. (2022). Symptom Burden and Immune Dynamics 6 to 18 Months Following Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-control Study. (external link)
• Smeets, Nori JL; Teunissen, Esther MM; van der Velden, Kim et al. (2022). Glomerular filtration rate in critically ill neonates and children: creatinine-based estimations versus iohexol-based measurements. (external link)
• Lillås, Bjørn Steinar; Tøndel, Camilla; Assmus, Jörg et al. (2021). Low birthweight is associated with lower glomerular filtration rate in middle-aged mainly healthy women. (external link)
• Moreno-Martinez, David; Aguiar, Patricio; Auray-Blais, Christiane et al. (2021). Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus. (external link)
• Blomberg, Bjørn; Mohn, Kristin Greve-Isdahl; Brokstad, Karl Albert et al. (2021). Long COVID in a prospective cohort of home-isolated patients. (external link)
• Baka‐Ostrowska, Małgorzata; Bolong, David T.; Persu, Cristian et al. (2021). Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open‐label, phase 3, dose‐titration study. (external link)
• Kuwelker, Kanika; Zhou, Fan; Blomberg, Bjørn et al. (2021). Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: A case-ascertained study. (external link)
• Arrieta, Antonio C; Ang, Jocelyn Y; Espinosa, Claudia et al. (2021). Pharmacokinetics and Safety of Single-dose Tedizolid Phosphate in Children 2 to <12 Years of Age. (external link)
• Casabona, Giacomo; Habib, Ahsan; Povey, Michael et al. (2021). Randomised controlled trial showed long-term efficacy, immunogenicity and safety of varicella vaccines in Norwegian and Swedish children. (external link)
• van der Veen, Sanne; Körver, Simon; Hirsch, A et al. (2021). Early start of enzyme replacement therapy in pediatric male patients with classical Fabry disease is associated with attenuated disease progression. (external link)
• Eide, Thea Tislevoll; Hufthammer, Karl Ove; Brun, Atle et al. (2021). Accuracy of single intravenous access iohexol GFR in children is hampered by marker contamination. (external link)
• Tøndel, Camilla; Marti, Hans Peter (2021). Cardiovascular changes in young renal failure patients. (external link)
• Trieu, Mai Chi; Bansal, Amit; Madsen, Anders et al. (2020). SARS-CoV-2-specific neutralizing antibody responses in Norwegian healthcare workers after the first wave of COVID-19 pandemic: a prospective cohort study. (external link)
• Mohn, Kristin Greve Isdahl; Brokstad, Karl Albert; Islam, Shahinul et al. (2020). Early Induction of Cross-Reactive CD8+ T-Cell Responses in Tonsils After Live-Attenuated Influenza Vaccination in Children. (external link)
• Thorsteinsdottir, Hjørdis; Salvador, Cathrin Lytomt; Mjøen, Geir et al. (2020). Growth Differentiation Factor 15 in Children with Chronic Kidney Disease and after Renal Transplantation. (external link)
• Najafian, Behzad; Tøndel, Camilla; Svarstad, Einar et al. (2020). Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss. (external link)
• Ramaswami, Uma; Bichet, Daniel G; Clarke, Lorne et al. (2019). Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial. (external link)
• Rittig, Søren; Baka-Ostrowska, Malgorzata; Tøndel, Camilla et al. (2019). The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation. (external link)
• Lillås, Bjørn Steinar; Tøndel, Camilla; Gjerde, Anna et al. (2019). Measurement of renal functional response using iohexol clearance-A study of different outpatient procedures. (external link)
• Spada, Marco; Baron, Ralf; Elliott, Perry M. et al. (2018). The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of experts. (external link)
• Salvador, Cathrin Lytomt; Tøndel, Camilla; Rowe, Alexander D. et al. (2018). Estimating glomerular filtration rate in children: evaluation of creatinine- and cystatin C-based equations. (external link)
• Sandbye, Christiane Lerche; Shroff, Rukshana; Wan, Mandy et al. (2018). Effects of nutritional Vitamin D supplementation on markers of bone and mineral metabolism in children with chronic kidney disease. (external link)
• Eikrem, Øystein Solberg; Skrunes, Rannveig; Tøndel, Camilla et al. (2017). Pathomechanisms of renal Fabry disease. (external link)
• Svarstad, Einar; Leh, Sabine Maria; Skrunes, Rannveig et al. (2017). Bedside stereomicroscopy of Fabry kidney biopsies: An easily available method for diagnosis and assessment of sphingolipid deposits. (external link)
• Salvador, Cathrin Lytomt; Tøndel, Camilla; Rowe, Alexander D. et al. (2017). Renal Function Influences Diagnostic Markers in Serum and Urine: A Study of Guanidinoacetate, Creatine, Human Epididymis Protein 4, and Neutrophil Gelatinase–Associated Lipocalin in Children. (external link)
• Suntjens, Eefje B.; Dreschler, Wouter Albert; Hess-Erga, Jeanette et al. (2017). Hearing loss in children with Fabry disease. (external link)
• Tøndel, Camilla; Salvador, Cathrin Lytomt; Hufthammer, Karl Ove et al. (2017). Iohexol plasma clearance in children: validation of multiple formulas and single-point sampling times. (external link)
• Skrunes, Rannveig; Tøndel, Camilla; Leh, Sabine Maria et al. (2017). Long-term dose-dependent agalsidase effects on kidney histology in fabry disease. (external link)
• Skrunes, Rannveig; Svarstad, Einar; Larsen, Kristin Kampevold et al. (2016). Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients. (external link)
• Najafian, Behzad; Tøndel, Camilla; Svarstad, Einar et al. (2016). One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease. (external link)
• Tøndel, Camilla; Bolann, Bjørn Johan; Salvador, Cathrin Lytomt et al. (2016). Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times. (external link)
• Mohn, Kristin Greve Isdahl; Brokstad, Karl Albert; Pathirana, Rishi et al. (2016). Live attenuated influenza vaccine in children induces b-cell responses in tonsils. (external link)
• Tøndel, Camilla; Kanai, Takahiro; Larsen, Kristin Kampevold et al. (2015). Foot process effacement is an early marker of nephropathy in young classic fabry patients without albuminuria. (external link)
• Mohn, Kristin Greve Isdahl; Bredholt, Geir; Brokstad, Karl Albert et al. (2015). Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children. (external link)
• Tol, Linda van der; Svarstad, Einar; Ortiz, Alberto et al. (2015). Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis. (external link)
• Salvador, Cathrin Lytomt; Tøndel, Camilla; Mørkrid, Lars et al. (2015). Glomerular filtration rate measured by iohexol clearance: A comparison of venous samples and capillary blood spots. (external link)
• Wijburg, Frits; Benichou, Bernard; Bichet, Daniel G et al. (2015). Characterization of early disease status in treatment-naive male paediatric patients with fabry disease enrolled in a randomized clinical trial. (external link)
• Biegstraaten, Marieke; Arngrímsson, R; Barbey, F et al. (2015). Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: The European Fabry Working Group consensus document. (external link)
• Mauer, Michael; Glynn, Emily; Svarstad, Einar et al. (2014). Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease. (external link)
• Tol, Linda van der; Cassiman, David; Houge, Gunnar et al. (2014). Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up. (external link)
• Tøndel, Camilla; Bostad, Leif; Larsen, Kristin Kampevold et al. (2013). Agalsidase Benefits Renal Histology in Young Patients with Fabry Disease. (external link)
• Tøndel, Camilla; Vikse, Bjørn Egil; Bostad, Leif et al. (2012). Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010. (external link)
• Linthorst, Gabor E.; Burlina, Allessandro; Cecchi, Franco et al. (2012). Recommendations on Reintroduction of Agalsidase Beta for Patients with Fabry Disease in Europe, Following a Period of Shortage. (external link)
• Najafian, Behzad; Svarstad, Einar; Bostad, Leif et al. (2011). Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. (external link)
• Tøndel, Camilla; Ramaswami, Uma; Aakre, Kristin Moberg et al. (2010). Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate. (external link)
• Guest, Julian F; Jenssen, Trond; Houge, Gunnar et al. (2010). Modelling the resource implications of managing adults with Fabry disease in Norway favours home infusion. (external link)
• Aakre, Kristin M.; Tøndel, Camilla; Brun, Atle et al. (2009). The MDRD equation may mask decline of glomerular filtration rate in Fabry patients with normal or nearly normal kidney function. (external link)
• Tøndel, Camilla; Ramaswami, Uma; Aakre, Kristin Moberg et al. (2009). Monitoring renal Function in Fabry children: comparisons of measured and creatinine-based estimated Glomerular Filtration Rate. (external link)
• Tøndel, Camilla; Bostad, Leif; Hirth, Asle et al. (2008). Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. (external link)
• Svarstad, Einar; Bostad, Leif; Kaarbøe, Øyvind et al. (2005). Focal and segmental glomerular sclerosis (FSGS) in a man and a woman with Fabry's disease. (external link)
• Tøndel, Camilla; Lægreid, Liv Marie; Hirth, Asle et al. (2003). [Intravenous Enzyme Substitution Therapy in Children With Fabry's Disease] . (external link)
• Juliusson, Petur Benedikt; Tøndel, Camilla; Aanderud, Sylvi et al. (2002). Behandling av Graves sykdom hos barn og unge. (external link)

Academic literature review

• Burlina, Allesandro; Brand, Eva; Hughes, Derralynn A. et al. (2023). An expert consensus on the recommendations for the use of biomarkers in Fabry disease. (external link)
• Tøndel, Camilla; Thurberg, Beth L.; DasMahapatra, Pronabesh et al. (2022). Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues. (external link)
• Wanner, Christoph; Arad, Michael; Baron, Ralf et al. (2018). European expert consensus statement on therapeutic goals in Fabry disease. (external link)

Feature article

• Gamlund, Espen; Alsheikh, Muath K; Bratlie, Sigrid et al. (2023). Uetisk å la være å satse på genteknologi. (external link)
• Bratlie, Sigrid; Holst-Jensen, Arne; Alsheikh, Muath K et al. (2023). På tide å åpne for genteknologi i norsk matproduksjon. (external link)
• Bratlie, Sigrid; Tøndel, Camilla; Alsheikh, Muath K et al. (2023). GMO-regler må ikke få stoppe utviklingen av avanserte terapier. (external link)

Letter to the editor

• Lillås, Bjørn Steinar Demma; Tøndel, Camilla; Melsom, Toralf et al. (2023). Response to Birth Weight and Renal Functional Reserve in Adults. (external link)

Reader opinion piece

• Bratlie, Sigrid; Alsheikh, Muath K; Brautaset, Trygve et al. (2023). Mer faglighet fra naturbevegelsen, takk. (external link)
• Bertelsen, Anne Kjørsvik; Tøndel, Camilla; Krohn, Jørgen Gitlesen et al. (2013). Small fibre neuropathy in Fabry disease. (external link)
• Houge, Gunnar; Tøndel, Camilla; Kaarbøe, Øyvind et al. (2011). Fabry or not Fabry – a question of ascertainment. (external link)

Report

• Wargelius, Anna; Alsheikh, Muath K; Gamlund, Espen et al. (2023). Genteknologi i en bærekraftig fremtid. (external link)

Academic lecture

• Tøndel, Camilla; Riisnes, Idunn; Leh, Sabine et al. (2021). Cleared Podocytes and Normal Kidney Function in Classical Fabry Males 15 Years After Start of Enzyme Replacement Therapy at Young Age. (external link)
• Strauss, Philipp; Eikrem, Øystein Solberg; Tøndel, Camilla et al. (2019). Fabry Nephropathy: First mRNA-seq Findings from Kidney Biopsies Before and After Enzyme Replacement Therapy. (external link)
• Mohn, Kristin Greve Isdahl; Cox, Rebecca Jane; Zhou, Fan et al. (2015). Cellular immune responses after live attenuated influenza vaccination in children, a clinical trial.. (external link)
• Tøndel, Camilla; Svarstad, Einar (2013). Podocytes: Therapeutic Target in Fabry Disease?. (external link)
• Tøndel, Camilla; Bostad, Leif; Svarstad, Einar (2010). 5 YEARS FOLLOW-UP RENAL BIOPSIES IN PAEDIATRIC AND ADULT FABRY PATIENTS ON ENZYME REPLACEMENT THERAPY. (external link)
• Haugen, Olav H.; Tøndel, Camilla; Svarstad, Einar (2009). Corneal changes in Fabry's disease. (external link)

Errata

• Tøndel, Camilla; Bolann, Bjørn Johan; Salvador, Cathrin Lytomt et al. (2016). Erratum to: Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times (Pediatric Nephrology, (2017), 32, 2, (311-320), 10.1007/s00467-016-3436-z). (external link)

Programme participation

• Tøndel, Camilla (2015). Liv og død-serien; Legemiddelutprøving hos barn. (external link)

Abstract

• Salvador, Cathrin Lytomt; Tøndel, Camilla; Mørkrid, Lars et al. (2013). GLOMERULAR FILTRATION RATE (GFR) MEASURED BY IOHEXOL CLEARANCE IN CHILDREN; A COMPARISON BETWEEN VENOUS SAMPLES AND DRIED BLOOD SPOTS. (external link)
• Wijburg, Frits; Benichou, Bernard; Bichet, Daniel G et al. (2013). A randomized, multicenter, multinational, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms: Baseline demographics and clinical data. (external link)
• Najafian, Behzad; Whitley, Chester; Thurberg, Beth et al. (2013). Renal structural-functional relationship (SFR) studies suggest that podocyte GL-3 accumulation predicts urine protein creatinine ratio in Fabry disease (FD) nephropathy (FDN). (external link)
• Najafian, Behzad; Glynn, Emily; Svarstad, Einar et al. (2012). Mosaicism of Podocyte Involvement in Untreated Females with Fabry Disease. (external link)
• Tøndel, Camilla; Bostad, Leif; Svarstad, Einar (2010). RENAL FOLLOW-UP BIOPSIES IN YOUNG MALE FABRY PATIENTS ON ENZYME REPLACEMENT THERAPY. (external link)
• Tøndel, Camilla; Ramaswami, Uma; Aakre, Kristin Moberg et al. (2009). Monitoring renal Function in Fabry children; estimated or measured glomerular Filtration rate?. (external link)
• Tøndel, Camilla; Bertelsen, Anne Kjørsvik; Bostad, Leif et al. (2009). Fabry Disease: Unusual Symptoms in two Boys Treated with Lamotrigine and Fabrazyme, Respectively. (external link)
• Tøndel, Camilla; Bostad, Leif; Lægreid, Liv Marie et al. (2008). Prominence of glomerular and vascular changes in renal biopsies in children and adolescents with Fabry disease and microalbuminuria. (external link)

See a complete overview of publications in Cristin.